RE:New interview with TLT Investor Relations - Michael BorovecGreat interview, but the planned NASDAQ uplisting foretells a future consolidation to meet the minimum listing requirements.
Hopefully, the TLC-2000 gets approved and revenues pick up substantially by then so the rollback is at most 3 to 1. Of course, approval of the CTA and progress with the human trials would help as well. Anyone who responds that the company will organically grow to $2 or $3 per share by then and will not need to do a share rollback is delusional. That almost never happens in the real world.
Also, I know the company recently "cashed-up" from the $8 Million private placement, but it also seems like Borovec was hinting at other possible future financings:
"We have recently participated in investor meetings in the United States, meeting with a number of financial institutions who own or have an interest in owning Theralase stock."
Hopefully, they don't further dilute us too much then announce a 10 to 1 rollback.
All that gloom and doom said, I have been long TLT for almost two years and am rightly optimistic that the future is bright. But I'm also a realist and know that corporate finance is a game of sharks who rarely care very much about the retail shareholder.